Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is \>= 18 years of age.~* Patient has clinical and/or pathological diagnosis of intra-hepatic portal hypertension.~* Patient has clinical diagnosis of cirrhosis.~* Patient has undergone variceal banding.~Exclusion Criteria:~* Patient has a Child-Pugh score \>12.~* Patient has portal hypertension resulting from hepatic vein obstruction, portal vein occlusion, schistosomiasis, portal vein thrombosis, splenic vein thrombosis, or Budd-Chiari syndrome.~* Variceal banding procedure was performed within 1 month of the screening visit.~* Patient has active or recurrent variceal bleeding, or has had variceal bleeding within the 12 weeks prior to screening.~* Patient is unwilling to discontinue use of vasoactive drugs from the screening visit through the end of the study.~* Patient has hepatocellular carcinoma that is being medically treated or is advanced.~* Patient has impaired renal function (i.e., serum creatinine concentration \>1.8 mg/dl)~* Patient has a history of liver transplant, or is expected to receive a liver transplant during the study period.~* Patient has undergone a gastrointestinal or abdominal surgical procedure within 90 days prior to the Screening Visit, or has had a bowel resection at any time.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo TID (Type: PLACEBO_COMPARATOR): Participants receive matching placebo capsules three times daily (TID)
- 12 mcg TID (Type: EXPERIMENTAL): Participants receive 12 mcg Cobiprostone TID
- 18 mcg TID (Type: EXPERIMENTAL): Participants receive 18 mcg Cobiprostone TID

Based on this trial design, predict the completion outcome and termination type (if applicable).